Risperidone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Risperidone Market is projected to expand from USD 6.36 Billion in 2025 to USD 8.58 Billion by 2031, reflecting a CAGR of 5.12%. As an atypical antipsychotic, risperidone is primarily employed in the management of schizophrenia, bipolar disorder, and autism-related irritability. Market stability is largely underpinned by increasing diagnostic rates for psychiatric conditions and the affordability of generic versions, which facilitates widespread access across healthcare systems worldwide. Additionally, the drug's proven effectiveness in stabilizing acute manic or psychotic episodes in both adult and pediatric patients ensures continuing demand.

However, market growth encounters a substantial hurdle regarding patient adherence, often compromised by adverse reactions such as weight gain and movement disorders. These safety concerns frequently lead prescribers to favor newer generation alternatives that offer improved tolerability. According to the International Federation of Pharmaceutical Manufacturers and Associations, mental health conditions impacted nearly one billion individuals globally in 2024. This extensive patient population underscores the urgent requirement for accessible treatments like risperidone, even amidst strong competitive pressure from novel therapeutic options.

Market Drivers

The rising global prevalence of schizophrenia and bipolar disorder serves as a major engine for the Global Risperidone Market, requiring continuous pharmacological support to control chronic symptoms. As patient numbers grow, healthcare systems face increasing pressure to ensure the availability of antipsychotic therapies to alleviate the societal impact of severe psychiatric illnesses. Data from the Substance Abuse and Mental Health Services Administration in July 2025, referencing the '2024 National Survey on Drug Use and Health', indicates that approximately 14.6 million adults in the United States were identified as having a serious mental illness in 2024, highlighting the immense need for effective therapeutic solutions. This growing disease burden correlates directly with higher prescription rates for established antipsychotics such as risperidone.

Simultaneously, the market is evolving through the increased uptake of long-acting injectable formulations aimed at improving patient compliance and minimizing relapse rates linked to inconsistent oral dosing. Pharmaceutical developers are leveraging this shift by launching advanced delivery systems that provide extended-release benefits. For example, Teva Pharmaceutical Industries reported in its January 2025 'Fourth Quarter and Full Year 2024 Financial Results' that global revenue for UZEDY, its extended-release risperidone injectable, hit $117 million in 2024, exceeding initial expectations. This transition toward advanced formulations is also apparent in emerging markets; Luye Pharma Group noted in 2025 that revenue from its central nervous system portfolio, including the risperidone microsphere Rykindo, rose by 5.4% in the first half of the year.

Market Challenges

Expansion of the risperidone market is directly impeded by safety issues involving adverse effects, particularly weight gain and movement disorders. These physical reactions often lead to suboptimal patient compliance, forming a significant obstacle to sustained usage. When patients undergo considerable metabolic shifts or involuntary muscle contractions, they frequently stop treatment or demand adjustments to their medication plans. Consequently, healthcare providers are compelled to explore alternative therapies with better tolerability, thereby diminishing the reliance on and market share of established options like risperidone.

The trend toward newer generation antipsychotics is driven by the clinical necessity to manage symptoms consistently without causing debilitating side effects. The scale of this issue is highlighted by the widespread prevalence of conditions needing ongoing care; the World Health Organization reported in 2024 that schizophrenia affects roughly 24 million people worldwide, a large demographic for whom treatment continuity is vital but often disrupted by drug intolerance. As a result, the existence of safer pharmacological alternatives constrains risperidone's revenue potential, as physicians increasingly emphasize patient quality of life and adherence when making prescribing choices.

Market Trends

The creation of Once-Weekly Oral Gastric-Resident Capsules represents a significant technological breakthrough aimed at closing the gap between daily oral compliance and invasive injectable treatments. This innovation utilizes a novel dosage form that remains in the stomach to release medication steadily over a seven-day span, effectively reducing the pill burden that often hinders treatment success in schizophrenia patients. By sustaining stable plasma levels without requiring injections, this approach tackles adherence issues while respecting patient autonomy. According to the HMP Global Learning Network in June 2025, the article 'Novel Long-Acting Oral Formulation of Risperidone Shows Promise in Phase 3 Trial' reported that the investigational weekly capsule LYN-005 maintained therapeutic concentrations in the STARLYNG-1 study, reaching a geometric mean ratio for minimum concentration of 1.04 at week five relative to daily immediate-release risperidone.

Concurrently, the introduction of Generic Extended-Release Injectables is altering the competitive environment by offering affordable alternatives to long-established branded microsphere products. The approval and release of complex generic variants of standard long-acting antipsychotics are breaking the market exclusivity once enjoyed by originator drugs, leading to substantial price reductions and broader access for payers and patients. This transition compels branded manufacturers to focus on newer delivery technologies, while generics seize market share in the mature injectable sector. For instance, Lupin Limited announced in November 2025, within its 'Lupin Launches Generic Risperidone Extended-Release Injectable Suspension' report, that it had released its generic option in the United States, aiming for a total annual addressable market valued at roughly $187 million.

Key Players Profiled in the Risperidone Market

• Otsuka Pharmaceutical Co., Ltd.
• AbbVie Inc.
• Dr. Reddy's Laboratories Ltd.
• Pfizer Inc.
• Endo International PLC
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Novartis AG
• Lupin Limited

Report Scope

In this report, the Global Risperidone Market has been segmented into the following categories:

Risperidone Market, by Route Of Administration:

• Injectable
• Oral
• Parenteral

Risperidone Market, by Application:

• Schizophrenia
• Bipolar Disorder
• Irritability Associated with Autistic Disorder
• Others

Risperidone Market, by End-Users:

• Hospitals
• Homecare
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Risperidone Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Risperidone Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.